CADL Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 2823 min ago

@ $11.45

Išleistas: 17 geg. 2024 @ 18:14

Grąža: 0.42%

Ankstesnis signalas: geg. 17 - 16:30

Ankstesnis signalas: Pardavimas

Grąža: -12.98 %

Live Chart Being Loaded With Signals

Commentary (17 geg. 2024 @ 23:00):

Stats
Šios dienos apimtis	833 352
Vidutinė apimtis	5.49M
Rinkos kapitalizacija	342.06M
EPS	$0 ( 2024-05-09 )
Kita pelno data	( $0 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.78
ATR14	$2.10 (18.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	25 000	Stock Option (Right to Buy)
2024-01-12	Schoch Charles	Sell	39 498	Stock Option (Right to Buy)
2023-11-28	Tyagarajan Seshu	Sell	17 328	Common Stock

INSIDER POWER
76.86
Last 92 transactions
Buy: 8 106 969 \| Sell: 4 393 086

Tūris Koreliacija

Ilgas: -0.58 (weak negative)

Trumpas: 0.74 (moderate)

Signal:(50) Neutral

Candel Therapeutics, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Candel Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos

-0.53
( weak negative )

-0.47
( neutral )

0.00
( neutral )

-0.66
( moderate negative )

0.13
( neutral )

0.71
( moderate )

Candel Therapeutics, Inc. Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$-1.20M (0.00 %)
EPS:	$-1.310

FY	2023
Pajamos:	$0
Bruto pelnas:	$-1.20M (0.00 %)
EPS:	$-1.310

FY	2022
Pajamos:	$125 000
Bruto pelnas:	$-862 000 (-689.60 %)
EPS:	$-0.0994

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.934

Financial Reports:

No articles found.

Candel Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.